You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 10,376,564


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,376,564
Title:Interleukin-2 for treating food allergy
Abstract: The present invention relates to the use of interleukin-2 (IL-2) for treating a food allergy, either by inducing non-specific tolerance against food allergens, or in a desensitization protocol in combination with a food allergen.
Inventor(s): Klatzmann; David (Paris, FR), Bellier; Bertrand (Paris, FR)
Assignee: SORBONNE UNIVERSITE (Paris, FR) ASSISTANCE PUBLIQUE--HOPITAUX DE PARIS (Paris, FR) CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris, FR)
Application Number:15/124,734
Patent Claims:1. A method for treating a food allergy in a subject comprising administering Interleukin-2 (IL-2) to said subject, wherein IL-2 is administered: (i) subcutaneously at a dosage of less than 5 MIU/day, (ii) orally at a dosage of between 0.5 and 10 MIU/day or (iii) intranasally at a dosage of between 0.5 and 5 MIU/day.

2. The method of claim 1, wherein the subject is afflicted with a food allergy selected from the group consisting of peanut allergy, milk allergy, nut allergy, corn allergy, fruit allergy, garlic allergy, oat allergy, shellfish allergy, soy allergy, wheat allergy, egg allergy, sesame allergy, olive oil allergy, cheese allergy, crustacean allergy, and fish allergy.

3. The method of claim 2, wherein the wheat allergy is gluten allergy.

4. The method of claim 1, wherein IL-2 is administered repeatedly.

5. The method of claim 1, wherein IL-2 is administered during a cyclic period that lasts from about 1 month to about one year, said cyclic period being optionally repeated every two or three years.

6. The method of claim 1, wherein said method reduces the risk, severity or occurrence of an allergic response or crisis.

7. The method of claim 1, wherein IL-2 is administered in combination with a food allergen.

8. The method of claim 2, wherein the subject is afflicted with an egg allergy.

9. The method of claim 1, wherein IL-2 is administered subcutaneously at a dosage of less than 5 MIU/day.

10. The method of claim 9, wherein IL-2 is administered subcutaneously at a dosage of less than 3.5 MIU/day.

11. The method of claim 10, wherein IL-2 is administered subcutaneously at a dosage of between 0.05 MIU and 2 MIU/day or between 0.1 and 3 MIU/day.

12. The method of claim 1, wherein IL-2 is administered orally at a dosage of between 0.5 and 10 MIU/day.

13. The method of claim 12, wherein IL-2 is administered orally at a dosage of between 1 and 5 MIU/day.

14. The method of claim 12, wherein IL-2 is administered orally at a dosage of between 5 and 10 MIU/day.

15. The method of claim 1, wherein IL-2 is administered intranasally at a dosage of between 0.5 and 5 MIU/day.

16. The method of claim 15, wherein IL-2 is administered intranasally at a dosage of between 1 and 5 MIU/day.

17. A method for treating a food allergy in a subject comprising administering Interleukin-2 (IL-2) to said subject, wherein IL-2 is administered subcutaneously, orally or intranasally at a dosage of 0.05 to 10 MIU/m.sup.2/day.

18. The method according to claim 1, wherein IL-2 is aldesleukin.

19. The method according to claim 17, wherein IL-2 is aldesleukin.

Details for Patent 10,376,564

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Clinigen, Inc. PROLEUKIN aldesleukin For Injection 103293 05/05/1992 ⤷  Try a Trial 2034-03-11
Aimmune Therapeutics, Inc. PALFORZIA peanut (arachis hypogaea) allergen powder Powder 125696 01/31/2020 ⤷  Try a Trial 2034-03-11
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.